Short course induction immunosuppression with thymoglobulin for renal transplant recipients

Transplantation. 2002 Feb 15;73(3):473-5. doi: 10.1097/00007890-200202150-00025.

Abstract

Background: The aim of this study was to demonstrate that 3-days of induction immunosuppression with thymoglobulin was as effective and safe as a 7-day course and reduced initial hospitalization after transplantation.

Methods: This was a prospective, nonrandomized trial of 40 consecutive patients receiving thymoglobulin induction for 3 days and followed for 1 year. An historical group of 48 patients that received 7 days of thymoglobulin served as controls.

Results: At 1 year, acute rejection (5 vs. 4%), graft survival (95 vs. 98%) and patient survival were similar; a composite end point of freedom from death, rejection, or graft loss, the event-free graft survival, was similar as was the safety profile. In the 3-day group, lymphocyte depletion was more sustained and initial hospitalization was significantly shorter (6 vs. 8 days).

Conclusion: Three-day induction with thymoglobulin is as effective and safe as seven days, decreases initial hospitalization and causes more sustained lymphocyte depletion.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antilymphocyte Serum / therapeutic use*
  • Female
  • Graft Rejection
  • Humans
  • Immunosuppression*
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Prospective Studies
  • T-Lymphocytes / immunology

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents